Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. Quantum BioPharma recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing the company to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS.
To view the full press release, visit https://ibn.fm/L1aXe
In brief
Quantum BioPharma says it will take part in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on Sept. 16, 2026. Co-founder and Executive Co-chairman Anthony Durkacz is scheduled to discuss the company’s recent progress and growth plans. The announcement also highlights the U.S. Food and Drug Administration’s approval of an Investigational New Drug application for Lucid-MS, which the company says permits it to start Phase 2 trials in patients with progressive multiple sclerosis. Lucid-MS is described by Quantum BioPharma as its lead compound and a program focused on multiple sclerosis. The company is developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates at different development stages.
Key takeaways
- Quantum BioPharma is scheduled to participate in the Toronto summit on Sept. 16, 2026.
- Anthony Durkacz will present the company’s milestones and growth strategy, according to the announcement.
- The company says FDA approval of its Lucid-MS application allows it to begin Phase 2 trials for progressive MS.
- Quantum BioPharma describes itself as developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders.
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Questions around this news
What will Quantum BioPharma present at the ArcStone-Kingswood Growth Summit?
The company said Co-founder and Executive Co-chairman Anthony Durkacz will present its recent milestones and future growth strategy. The presentation is scheduled for the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026.
What does FDA approval of an Investigational New Drug application allow for Lucid-MS?
The release says the FDA approved the Investigational New Drug application for Lucid-MS, allowing Quantum BioPharma to begin Phase 2 trials in patients with progressive multiple sclerosis. This approval relates to permission to proceed with clinical testing; it does not establish that the candidate is effective or approved as a treatment.
What does the release say about Lucid-MS and myelin degradation?
Quantum BioPharma describes Lucid-MS as its lead compound and a patented new chemical entity. It says the candidate was shown to prevent and reverse myelin degradation in preclinical models. The release identifies myelin degradation as the underlying mechanism of multiple sclerosis and says the planned Phase 2 trials will involve patients with progressive MS.
How are royalty payments from unbuzzd described in the release?
The release says Quantum BioPharma’s agreement with Unbuzzd includes royalties based on sales of unbuzzd. The stated rate is 7% until payments to Quantum reach $250 million, after which the rate becomes 3% in perpetuity. The release also says Quantum retains rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
SEC filings
Earlier from Quantum BioPharma Ltd.
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
